Market cap
$12 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 3.85 | -6.60 | -47.00 |
| EBIT | -67.88 | 108.98 | -90.19 | -204.95 | -229.86 |
| Net Profit | -243.28 | 90.56 | 64.20 | 12.45 | -2.04 |
| EPS | -242.19 | 90.68 | 65.85 | 19.82 | 9.85 |
| Book Value | -- | -- | -61.00 | -33.69 | -31.14 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -3,851.34 | -3,743.90 | -11,453.03 | -4,992.86 | -3,905.73 |
| Net Margin
| -- | -- | -2,118.86 | -- | -- |
| Return on equity
| -76.11 | -62.07 | -60.38 | -86.34 | -69.10 |
| Return on Capital
| -71.91 | -59.13 | -- | -83.10 | -65.26 |
| Return on Assets
| -58.72 | -48.94 | -29.94 | -68.32 | -53.98 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.03 | 0.05 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
-83.10
|
-65.26
|
-67.37
|
-42.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-60.38
Lower than Peers by 22.78
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-60.38
|
-86.34
|
-69.10
|
-72.89
|
-44.46
|
|
Peer Median
|
-37.60
|
--
|
--
|
--
|
--
|
ROA
-29.94
Higher than Peers by 13.12
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-29.94
|
-68.32
|
-53.98
|
-53.87
|
-36.18
|
|
Peer Median
|
-43.06
|
--
|
--
|
--
|
--
|
EBIT Margin
-11,453.03
Lower than Peers by 11,412.31
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-11,453.03
|
-4,992.86
|
-3,905.73
|
-2,655.42
|
-3,561.21
|
|
Peer Median
|
-40.72
|
--
|
--
|
--
|
--
|
Net Margin
-2,118.86
Lower than Peers by 2,041.06
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-2,118.86
|
-4,896.50
|
-3,738.02
|
-2,638.83
|
-3,517.79
|
|
Peer Median
|
-77.79
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.01
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-0.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
3.85
Lower than Peers by 252.89
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
3.85
|
-0.14
|
-0.17
|
0.64
|
-0.04
|
|
Peer Median
|
256.74
|
--
|
--
|
--
|
--
|
EBIT Growth
-90.19
Lower than Peers by 104.24
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-90.19
|
-9.52
|
-22.52
|
-22.33
|
5.08
|
|
Peer Median
|
14.05
|
--
|
--
|
--
|
--
|
Net Profit Growth
64.20
Higher than Peers by 50.63
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
64.20
|
-12.23
|
-17.99
|
-23.07
|
3.36
|
|
Peer Median
|
13.57
|
--
|
--
|
--
|
--
|
EPS Growth
65.85
Higher than Peers by 33.01
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
65.85
|
-0.02
|
0.13
|
0.15
|
0.04
|
|
Peer Median
|
32.84
|
--
|
--
|
--
|
--
|
Book Value Growth
-44.75
Lower than Peers by 22.23
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-44.75
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-22.52
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
0.03
|
0.05
|
0.08
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
0.03
|
0.01
|
0.02
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.63
Lower than Peers by 0.98
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
4.63
|
3.29
|
5.53
|
4.29
|
4.33
|
|
Peer Median
|
5.61
|
--
|
--
|
--
|
--
|
Quick Ratio
4.63
Lower than Peers by 0.89
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
4.63
|
3.10
|
5.57
|
4.11
|
4.26
|
|
Peer Median
|
5.52
|
--
|
--
|
--
|
--
|
Interest Coverage
-198.44
Lower than Peers by 195.86
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
-198.44
|
-386.51
|
-681.73
|
-233.17
|
-63.94
|
|
Peer Median
|
-2.57
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
15.50
|
60.55
|
34.92
|
111.92
|
|
Peer Median
|
40.61
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.08
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
0.01
|
0.01
|
0.01
|
0.02
|
0.01
|
|
Peer Median
|
0.10
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
157.37
|
187.14
|
188.37
|
373.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
1,490.85
|
450.81
|
912.20
|
1,348.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
9,024.13
|
3,147.65
|
2,452.00
|
5,067.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
-7,375.91
|
-2,509.70
|
-1,351.43
|
-3,344.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
-0.29
|
-4.82
|
-4.05
|
-2.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.35
Lower than Peers by 2.49
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
0.35
|
0.41
|
2.65
|
3.19
|
1.21
|
|
Peer Median
|
2.84
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.48
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
0.48
|
0.35
|
-2.94
|
-3.09
|
-0.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
12
Higher than Peers by 10
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Vascular Biogenics - ADR
|
12
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3
|
--
|
--
|
--
|
--
|